Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1066 participants.
Also called NCT01807221
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,066 participants
- Sponsor
- Registry
-
NCT01807221 -
2012-002627-15
-
- Main results
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Lithuania, Netherlands, Norway, Poland, Portugal, South Africa, South Korea, Spain, Sweden, Taiwan, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01807221. Randomized; quadruple masking; primary purpose treatment. Start 2013-06-17 (actual); primary completion 2014-11-11 (actual). Results posted on 2021-06-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
- Acronym
- ARTS-HF
- Condition
- Heart Failure
- Intervention (Drug)
- Finerenone (BAY94-8862)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Inspra (eplerenone)
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01807221- Content hash
e8ba0e3c23b3599a55d36784835a88272127ef6441c8f0866b719e3476f2afcd